A Phase 4 interventional study of Valsartan/amlodipine 80/5 mg tablets and Amlodipine 5 mg capsules in Hypertension, sponsored by Novartis Pharmaceuticals. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-03-11.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 227 studies in Hypertension by Novartis — 4 open to participants now, 5 under way, none of them phase 3. Hypertension · Novartis.
Among the 227 studies in Hypertension by Novartis, this one is the 96th largest by enrollment of the 222 interventional ones that give a count, is one of 25 that started in 2008, is one of 67 in phase 4, and was the 132nd registered.
6,120 studies on the registry are indexed under Hypertension; 909 are open to participants now.
Browse Hypertension studies →4 of the 227 studies in Hypertension by Novartis are open now, in 4 countries. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in United Arab Emirates
Ages 18–99
Novartis Pharmaceuticals · Sites in Japan
Ages 18–60 · Healthy volunteers
Novartis Pharmaceuticals · Sites in United States
Ages 18–75
Novartis Pharmaceuticals · Sites in United States, Japan, Singapore
Ages 18+
By country, each count listing its studies:
Of the 558 Hypertension studies recruiting now, 265 (47%) set no upper age limit and 197 (35%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
227 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 18 · Phase 2 31 · Phase 3 109 · Phase 4 67
First in 1989; this study’s year is marked. 25 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 393 is above the median of 100 across 4,579 interventional studies indexed under Hypertension.
Median enrollment 309 across the 222 interventional studies, 813 across the 4 observational. Of the 219 that completed or were terminated, 88 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
3 of the studies in Hypertension by Novartis that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07644364Novartis PharmaceuticalsHJB647 Phase 1b Study in Japanese Healthy Participants With Elevated Blood Pressure and Patients With Hypertension | 2026-12-25 |
| NCT07610278Novartis PharmaceuticalsA Study to Evaluate the Pharmacodynamics of a Combination of QCZ484 and Inclisiran in Participants With Hypertension and Concomitant Hypercholesterolemia | 2027-04-28 |
| NCT07465666Novartis PharmaceuticalsA Real-world Study of the Effectiveness of Angiotensin Receptor-Neprilysin Inhibitor Therapy in Hypertensive Patients in the United Arab Emirates | 2027-08-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 227 studies in Hypertension by Novartis, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Assess that for an equivalent brachial blood pressure (BP)lowering, a fixed dose combination amlodipine/valsartan based regimen reduces central aortic BP pressure to a larger extent than an atenolol/amlodipine combination based regimen.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients were treated with valsartan/amlodipine 80/5 mg for 8 weeks followed by forced uptitration to valsartan/amlodipine 160/10 mg for 16 weeks. All doses were taken orally once daily in the morning, except on days when clinic visits were scheduled.
Drug: Valsartan/amlodipine 80/5 mg tablets
Patients were treated with atenolol/amlodipine 50/5 mg for 8 weeks followed by forced uptitration to atenolol/amlodipine 100/10 mg for 16 weeks. All doses were taken orally once daily in the morning, except on days when clinic visits were scheduled.
Drug: Amlodipine 5 mg capsules · Drug: Amlodipine 10 mg capsules · Drug: Atenolol 50 mg tablets · Drug: Atenolol 100 mg tablets
Change From Baseline of Central Systolic Blood Pressure (SBP) at Week 24 (Radial Measurement)
Time frame: Baseline and Week 24
Change From Baseline of Central Systolic Blood Pressure (SBP) at Week 8 (Radial Measurement)
Time frame: Baseline and Week 8
Change From Baseline of Central Pulse Pressure at Week 24 (Radial Measurement)
Time frame: Baseline and Week 24
Change From Baseline of Augmentation Index (Aix) at Week 8
To calculate the blood pressure augmentation index, the inflection point of the pressure curve corresponding to the return of the reflection wave was determined. The ratio between the pressure located above and below the inflection point was calculated.
Time frame: Baseline and Week 8
Change From Baseline of Aix at Week 24
Time frame: Baseline and Week 24
Change From Baseline of Aix Corrected to Heart Rate at Week 24
The heart rate correction was computed by a multivariate model analysis
Time frame: Baseline and Week 24
Change From Baseline of Pulse Wave Velocity at Week 24 (Radial Measurement)
Time frame: Baseline and Week 24
Change From Baseline of Brachial SBP/DBP at Week 24 (Tonometry Center)
Applanation tonometry is a measurement of aortic pressure and vascular stiffness. To assess the central aortic blood pressure, it is necessary to calibrate the applanation tonometry device using the brachial blood pressure.
Time frame: Baseline and Week 24
Change From Baseline of Brachial Pulse Pressure at Week 24 (Tonometry Center)
Time frame: Baseline and Week 24
Change From Baseline of SBP/DBP at Week 24 (Office BP)
Time frame: Baseline and Week 24
Change From Baseline of Pulse Pressure at Week 24 (Office BP)
Time frame: Baseline and Week 24
| Milestone | Valsartan/Amlodipine 160/10 mg | Atenolol/Amlodipine 100/10 mg |
|---|---|---|
| Started | 193 | 200 |
| Completed | 169 | 162 |
| Not completed | 24 | 38 |
| Withdrew: Adverse event | 18 | 28 |
| Withdrew: Lack of efficacy | 2 | 3 |
| Withdrew: Protocol violation | 1 | 2 |
| Withdrew: Administrative reasons | 0 | 2 |
| Withdrew: Withdrawal by subject | 3 | 3 |
| mmHg | Valsartan/Amlodipine 160/10 mg | Atenolol/Amlodipine 100/10 mg |
|---|---|---|
| Change From Baseline of Central Systolic Blood Pressure (SBP) at Week 24 (Radial Measurement) | -13.65 ± 1.15 | -9.7 ± 1.09 |
| mmHg | Valsartan/Amlodipine 160/10 mg | Atenolol/Amlodipine 100/10 mg |
|---|---|---|
| Change From Baseline of Central Systolic Blood Pressure (SBP) at Week 8 (Radial Measurement) | -10.92 ± 1.18 | -8.3 ± 1.12 |
| mmHg | Valsartan/Amlodipine 160/10 mg | Atenolol/Amlodipine 100/10 mg |
|---|---|---|
| Change From Baseline of Central Pulse Pressure at Week 24 (Radial Measurement) | -5.5 ± 0.65 | -1.7 ± 0.63 |
To calculate the blood pressure augmentation index, the inflection point of the pressure curve corresponding to the return of the reflection wave was determined. The ratio between the pressure located above and below the inflection point was calculated.
| Ratio | Valsartan/Amlodipine 160/10 mg | Atenolol/Amlodipine 100/10 mg |
|---|---|---|
| Change From Baseline of Augmentation Index (Aix) at Week 8 | -2.21 ± 0.78 | 3.61 ± 0.76 |
| Ratio | Valsartan/Amlodipine 160/10 mg | Atenolol/Amlodipine 100/10 mg |
|---|---|---|
| Change From Baseline of Aix at Week 24 | -4.10 ± 0.72 | 2.40 ± 0.70 |
The heart rate correction was computed by a multivariate model analysis
| Ratio | Valsartan/Amlodipine 160/10 mg | Atenolol/Amlodipine 100/10 mg |
|---|---|---|
| Change From Baseline of Aix Corrected to Heart Rate at Week 24 | -4.12 ± 0.67 | -2.43 ± 0.66 |
| m/s | Valsartan/Amlodipine 160/10 mg | Atenolol/Amlodipine 100/10 mg |
|---|---|---|
| Change From Baseline of Pulse Wave Velocity at Week 24 (Radial Measurement) | -0.98 ± 0.18 | -0.95 ± 0.17 |
Applanation tonometry is a measurement of aortic pressure and vascular stiffness. To assess the central aortic blood pressure, it is necessary to calibrate the applanation tonometry device using the brachial blood pressure.
| mmHg | Valsartan/Amlodipine 160/10 mg | Atenolol/Amlodipine 100/10 mg |
|---|---|---|
| SBP | -12.93 ± 1.14 | -11.78 ± 1.11 |
| DBP | -7.85 ± 0.70 | -7.94 ± 0.68 |
| mmHg | Valsartan/Amlodipine 160/10 mg | Atenolol/Amlodipine 100/10 mg |
|---|---|---|
| Change From Baseline of Brachial Pulse Pressure at Week 24 (Tonometry Center) | -5.02 ± 0.72 | -3.66 ± 0.70 |
| mmHg | Valsartan/Amlodipine 160/10 mg | Atenolol/Amlodipine 100/10 mg |
|---|---|---|
| SBP | -14.49 ± 1.08 | -16.94 ± 1.07 |
| DBP | -8.17 ± 0.72 | -10.45 ± 0.71 |
| mmHg | Valsartan/Amlodipine 160/10 mg | Atenolol/Amlodipine 100/10 mg |
|---|---|---|
| Change From Baseline of Pulse Pressure at Week 24 (Office BP) | -6.32 ± 0.81 | -6.48 ± 0.81 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Amlodipine 5 mg | — | 3/393 (0.8%) | 10/393 (2.5%) |
| Valsartan/Amlodipine 160/10 mg | — | 4/193 (2.1%) | 30/193 (15.5%) |
| Atenolol/Amlodipine 100/10 mg | — | 4/200 (2%) | 31/200 (15.5%) |
| Event | Amlodipine 5 mg | Valsartan/Amlodipine 160/10 mg | Atenolol/Amlodipine 100/10 mg |
|---|---|---|---|
| Colitis ulcerativeGastrointestinal disorders | 0/393 | 1/193 | 0/200 |
| Lip and/or oral cavity cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/393 | 1/193 | 0/200 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 0/393 | 1/193 | 0/200 |
| Cyst removalSurgical and medical procedures | 0/393 | 1/193 | 0/200 |
| Joint arthroplastySurgical and medical procedures | 0/393 | 1/193 | 0/200 |
| Head injuryInjury, poisoning and procedural complications | 0/393 | 0/193 | 1/200 |
| Neoplasm malignantNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/393 | 0/193 | 1/200 |
| PregnancyPregnancy, puerperium and perinatal conditions | 0/393 | 0/193 | 1/200 |
| Suicide attemptPsychiatric disorders | 0/393 | 0/193 | 1/200 |
| Inguinal hernia repairSurgical and medical procedures | 0/393 | 0/193 | 1/200 |
| Event | Amlodipine 5 mg | Valsartan/Amlodipine 160/10 mg | Atenolol/Amlodipine 100/10 mg |
|---|---|---|---|
| Oedema peripheralGeneral disorders | 10/393 | 30/193 | 31/200 |
| Age Continuous(years) | Valsartan/Amlodipine 160/10 mg | Atenolol/Amlodipine 100/10 mg | Total |
|---|---|---|---|
| Mean | 57.5 ± 9.94 | 56.2 ± 11.09 | 56.9 ± 10.55 |
| Sex: Female, Male(Participants) | Valsartan/Amlodipine 160/10 mg | Atenolol/Amlodipine 100/10 mg | Total |
|---|---|---|---|
| Female | 82 | 101 | 183 |
| Male | 111 | 99 | 210 |
| Region of Enrollment(participants) | Valsartan/Amlodipine 160/10 mg | Atenolol/Amlodipine 100/10 mg | Total |
|---|---|---|---|
| France | 193 | 200 | 393 |
The record gives a start of Jan 2008, a primary completion of Jan 2009 and a completion of Jan 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2011, 2 years after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.